ADT1324-Iratumumab Biosimilar-Anti-TNFRSF8/CD30 mAb-Research Grade
- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1324 |
Product Name |
ADT1324-Iratumumab Biosimilar-Anti-TNFRSF8/CD30 mAb-Research Grade |
Clonity |
Monoclonal |
|
Alternate Names anti-mouse TNFRSF8 antibody, anti-TNFRSF8 antibody, anti TNFRSF8 antibody, recombinant TNFRSF8, TNFRSF8 antibody, anti-TNFRSF8 monoclonal antibody, TNFRSF8 antibodies, TNFRSF8 recombinant antibody, TNFRSF8 blocking antibody, CD30 recombinant antibody, CD30 blocking antibody |
|
Alias |
MDX-060 |
Host |
CHO Cells |
Species |
Human |
Target |
TNFRSF8/CD30 |
Gene ID |
943 |
Isotype |
IgG1 Kappa |
Size |
1mg, 5mg |
Research Area |
Cancer |
CAS Number |
640735-09-7 |
Product Description |
Iratumumab is a human monoclonal antibody used in the treatment of oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's disease. This drug was developed by Medarex, which was later acquired by Bristol-Myers Squibb. |
Mechanism of Action |
Iratumumab is a monoclonal antibody targeting specific cancer-associated antigens. |
Metabolism |
Iratumumab has a long half-life and is distributed throughout the bloodstream and tissues. |
Application |
IP, IF, Functional assay, FC, Neut, ELISA, ICC |
Purity |
>95% as determined by SDS-PAGE |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
Reactivity |
Human |
Reference |
1. Veyri M, et al. Br J Haematol, 2023 Jun. PMID 37170397
2. Kadin ME, et al. Aesthet Surg J, 2023 Feb 3. PMID 35999655
3. Tsuyama N, et al. Histopathology, 2022 Sep. PMID 35789115
|





